YUNNAN BAIYAO(SZ:000538)2026-01-23 10:14Group 1: Product Development and Clinical Research - The pharmaceutical division is focusing on the secondary development of key products, including clinical studies on Yunnan Baiyao (powder and capsules) for diabetic foot and bone pain, and Gongxue Ning capsules for treating abnormal uterine bleeding [2][3] - Recent clinical research results show Gongxue Ning capsules effectively reduce post-abortion vaginal bleeding and complications, with good overall safety [3] - The Qi Xue Kang oral solution is undergoing multi-center clinical studies for hypertension, with the first patient enrolled successfully [3] Group 2: Business Strategy and Market Expansion - The provincial pharmaceutical company aims to enhance market share in existing hospitals and distribution channels through a "double rise and double drop" strategy, focusing on non-drug businesses and new specialty pharmacies [4] - Efforts will be made to optimize supply chain management and improve accounts receivable and inventory structure, aiming for a patient-centered healthcare ecosystem [4] Group 3: Online Sales Performance - The pharmaceutical division's O2O sales increased by over 20% in the first half of 2025, with significant online marketing efforts boosting product awareness and sales [6] - During the 2025 "618" shopping festival, Yunnan Baiyao toothpaste ranked first in the domestic market share across all channels [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.16 billion CNY, which represents 90.09% of the net profit attributable to shareholders [7][8] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares will be distributed, amounting to 1.82 billion CNY, with special dividends accounting for 50.05% of the net profit for that period [8]